HK Stock Market Move | KINTOR PHARMA-B (09939) rose more than 24% in the afternoon, with the unveiling of Phase III of KX-826 imminent, showing promising potential in the domestic FIC market.

KINTOR PHARMA-B (09939) rose more than 24% in the afternoon, as of the time of writing, it was up 23.38% at 3.8 Hong Kong dollars, with a trading volume of 29.0272 million Hong Kong dollars. In terms of news, recently, Kintor Pharmaceuticals announced on its investment platform that its self-developed topical androgen receptor (AR) antagonist KX-826, a 1.0% solution for the treatment of male androgenetic alopecia (AGA), will officially disclose its phase III clinical trial top-line data in mid to late March 2026. Previously, Softbank China released a research report stating that KX-826's phase III clinical trial results of a 5% Clascoterone solution targeting the same global target as of December 3, 2025, showed positive top-line results. This indicates that the mechanism of action of treating AGA by blocking the AR signaling pathway has been validated, and KX-826 has the potential to be a breakthrough in the AGA treatment field in nearly 30 years. The report pointed out that KX-826 has potential for domestic FIC, and the announcement of key data results, successful commercialization, or licensing authorization for commercialization in overseas regions will serve as valuation catalysts for the company.